HRP20070322T3 - Pellets containing venlafaxine hydrochloride - Google Patents

Pellets containing venlafaxine hydrochloride

Info

Publication number
HRP20070322T3
HRP20070322T3 HR20070322T HRP20070322T HRP20070322T3 HR P20070322 T3 HRP20070322 T3 HR P20070322T3 HR 20070322 T HR20070322 T HR 20070322T HR P20070322 T HRP20070322 T HR P20070322T HR P20070322 T3 HRP20070322 T3 HR P20070322T3
Authority
HR
Croatia
Prior art keywords
venlafaxine hydrochloride
weight
pellets containing
containing venlafaxine
hydrochloride
Prior art date
Application number
HR20070322T
Other languages
English (en)
Croatian (hr)
Inventor
Fekete P�l
Korb�ly Tibor
Bozso Agnes
Moricz Eszter
Original Assignee
Egis Gy�gyszergy�r Nyrt.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Egis Gy�gyszergy�r Nyrt. filed Critical Egis Gy�gyszergy�r Nyrt.
Publication of HRP20070322T3 publication Critical patent/HRP20070322T3/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1611Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5026Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HR20070322T 2003-10-10 2007-07-16 Pellets containing venlafaxine hydrochloride HRP20070322T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU0303382A HUP0303382A2 (hu) 2003-10-10 2003-10-10 Venlafaxin-hidroklorid-tartalmú pelletek
PCT/HU2004/000095 WO2005034930A1 (en) 2003-10-10 2004-10-08 Pellets containing venlafaxine hydrochloride

Publications (1)

Publication Number Publication Date
HRP20070322T3 true HRP20070322T3 (en) 2007-09-30

Family

ID=90001704

Family Applications (2)

Application Number Title Priority Date Filing Date
HR20060136A HRP20060136A2 (en) 2003-10-10 2006-04-07 Pellets containing venflaxine hydrochloride
HR20070322T HRP20070322T3 (en) 2003-10-10 2007-07-16 Pellets containing venlafaxine hydrochloride

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HR20060136A HRP20060136A2 (en) 2003-10-10 2006-04-07 Pellets containing venflaxine hydrochloride

Country Status (23)

Country Link
EP (1) EP1677777B1 (xx)
CN (1) CN1882321B (xx)
AT (1) ATE359771T1 (xx)
AU (1) AU2004280132B2 (xx)
BG (1) BG109539A (xx)
CY (1) CY1106693T1 (xx)
CZ (1) CZ2006269A3 (xx)
DE (1) DE602004006009T2 (xx)
DK (1) DK1677777T3 (xx)
EA (1) EA009695B1 (xx)
ES (1) ES2285538T3 (xx)
HK (1) HK1098364A1 (xx)
HR (2) HRP20060136A2 (xx)
HU (1) HUP0303382A2 (xx)
IL (1) IL174830A (xx)
NO (1) NO20062082L (xx)
PL (2) PL1677777T3 (xx)
PT (1) PT1677777E (xx)
RS (2) RS52150B (xx)
SI (1) SI1677777T1 (xx)
SK (1) SK50442006A3 (xx)
UA (1) UA82268C2 (xx)
WO (1) WO2005034930A1 (xx)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
RU2230556C2 (ru) 1999-10-29 2004-06-20 Эро-Селтик, С.А. Препаративные формы гидрокодона с контролируемым высвобождением
AU2002227383B2 (en) 2000-10-30 2004-07-08 Euro-Celtique S.A. Controlled release hydrocodone formulations
IL146462A (en) 2001-11-13 2015-02-26 Lycored Bio Ltd Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
US20080193524A1 (en) * 2005-07-28 2008-08-14 Dr. Reddy's Laboratories Ltd. Extended Release Venlafaxine Compositions
EA014262B1 (ru) * 2006-05-19 2010-10-29 Эгиш Дьёдьсердьяр Ньильваношан Мюкёдё Ресвеньтаршашаг Способ получения гранулированной массы
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
EP2579857A1 (en) * 2010-05-11 2013-04-17 Cima Labs Inc. Alcohol-resistant extended release dosage forms comprising venlafaxine
JP2013526523A (ja) 2010-05-11 2013-06-24 シマ ラブス インク. メトプロロールを含むアルコール耐性持続放出性経口剤形
EA201590776A1 (ru) * 2012-12-19 2015-11-30 Ратиофарм Гмбх Пеллеты с пленочным покрытием
CN103893151B (zh) * 2012-12-31 2018-04-27 石药集团中奇制药技术(石家庄)有限公司 一种盐酸文拉法辛缓释胶囊及其制备方法
WO2015065547A1 (en) 2013-10-31 2015-05-07 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
WO2020225773A1 (en) 2019-05-07 2020-11-12 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
US20220062200A1 (en) 2019-05-07 2022-03-03 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
EP1331003B1 (en) * 1996-03-25 2015-08-26 Wyeth LLC Extended release formulation containing venlafaxine
UA77145C2 (en) * 1997-11-05 2006-11-15 Wyeth Corp Extended release dosage formulation
CN1334080A (zh) * 2001-07-25 2002-02-06 成都康弘制药有限公司 盐酸万拉法新缓释片及其制备方法
IL146462A (en) * 2001-11-13 2015-02-26 Lycored Bio Ltd Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
AU2003219117A1 (en) * 2002-03-28 2003-10-13 Synthon B.V. Extended release venlafaxine formulations

Also Published As

Publication number Publication date
BG109539A (bg) 2006-11-30
EP1677777A1 (en) 2006-07-12
PL379541A1 (pl) 2006-10-02
DK1677777T3 (da) 2007-09-03
HUP0303382D0 (en) 2003-12-29
PT1677777E (pt) 2007-06-21
WO2005034930A1 (en) 2005-04-21
SK50442006A3 (sk) 2006-08-03
EA200600675A1 (ru) 2006-08-25
PL1677777T3 (pl) 2007-08-31
DE602004006009D1 (de) 2007-05-31
ES2285538T3 (es) 2007-11-16
AU2004280132A1 (en) 2005-04-21
RS20060252A (xx) 2008-08-07
CN1882321A (zh) 2006-12-20
HUP0303382A2 (hu) 2005-08-29
HRP20060136A2 (en) 2006-06-30
CN1882321B (zh) 2011-06-08
NO20062082L (no) 2006-05-09
CZ2006269A3 (cs) 2006-07-12
IL174830A0 (en) 2008-04-13
IL174830A (en) 2010-04-15
EA009695B1 (ru) 2008-02-28
EP1677777B1 (en) 2007-04-18
HK1098364A1 (en) 2007-07-20
RS52150B (en) 2012-08-31
AU2004280132B2 (en) 2009-10-22
SI1677777T1 (sl) 2007-10-31
DE602004006009T2 (de) 2008-01-10
UA82268C2 (uk) 2008-03-25
CY1106693T1 (el) 2012-05-23
ATE359771T1 (de) 2007-05-15

Similar Documents

Publication Publication Date Title
HRP20070322T3 (en) Pellets containing venlafaxine hydrochloride
RS52472B (en) SOLID DOSAGE FORM CONTAINING PROTON PUMP INHIBITOR AND ITS SUSPENSION
EA200700201A1 (ru) Композиция таблетки пролонгированного высвобождения, содержащая прамипексол или его фармацевтически приемлемую соль, способ ее изготовления и ее применение
EA200700049A1 (ru) Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
PE57599A1 (es) Composiciones que contienen tetrahidrolipstatina
RS51746B (sr) Atorvastatin kalcijum u farmaceutskom obliku, njegovoj smeši i farmaceutskoj formulaciji, koja sadrži atorvastatin kalcijum
AR072329A2 (es) Composicion farmaceutica que comprende nateglinida
ATE331525T1 (de) Salzformarme polyallylamine
AR037260A1 (es) Formulaciones de proteinas de liberacion sostenida acuosas
TR200401793T4 (tr) Perindopril tuzu ve bunu içeren farmasötik bileşimler.
IS2393B (is) Lyfjablanda sem felur í sér N-((1-N-bútýl-4-píperídínýl)metýl)-3,4-díhýdró-2H-(1,3)oxasínó(3,2-A)indól-10-karboxamíð eða salt og aðferð þar að lútandi sem felur í sér þurrkornamyndun
DK1501484T3 (da) Fremgangsmåde til fremstilling af tabletter ud fra farmaceutisk aktive stoffer som har uönskede tabletteringsegenskabler, med en granuleringsvæske der omfatter mikrokrystallinsk cellulose
EA200702496A1 (ru) Местная композиция, содержащая желатин
EA201170784A1 (ru) Гранулы тамсулозина для фиксированной комбинации
MXPA03011317A (es) Comprimido masticable que comprende paracetamol.
JP2011516544A5 (xx)
RS51578B (en) SOLID PHARMACEUTICAL COMPOSITION CONTAINING TELITROMYCIN
EA200801875A1 (ru) Антагонист cd 80
MXPA05008403A (es) Uso de acido comestible en formas de dosis solidas farmaceuticas de rapida dispersion.
DE60220551D1 (de) Tabletten mit verzögerter wirkstofffreisetzung enthaltend indapamid
EA200900249A1 (ru) Фармацевтическая композиция и способ ее получения
EA200500175A1 (ru) Соль морфин-6-глюкуронида
ATE553184T1 (de) Hefe konditionierung
ATE465718T1 (de) Feste pharmazeutische zubereitung enthaltend levothyroxin- und/oder liothyroninsalze
EA200500687A1 (ru) Применение дистронциевой соли 2-[n,n-ди(карбоксиметил)амино]-3-циано-4-карбоксиметилтиофен-5-карбоновой кислоты при получении лекарственных средств, предназначенных для лечения гастродуоденальной боли